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ABSTRACT
Pannexin 3 (Panx3) is a mechanosensitive, channel-forming glycoprotein implicated in the
progression of post-traumatic osteoarthritis. Despite evidence for Panx3 expression in
intervertebral discs (IVDs), its function here remained unknown. Using Panx3-/- mice, this
study investigated the role of Panx3 in age-associated and injury-induced models of IVD
degeneration. While loss of Panx3 did not significantly impact the progression of ageassociated IVD degeneration, it was associated with a protective phenotype in an injury
model of IVD degeneration, specifically in the annulus fibrosus (AF). Following IVD
injury, WT mice showed an accumulation of enlarged cells that appeared to contribute to
disrupted AF structure. In Panx3-/- IVDs, enlarged cells were rarely detected and AF
structure was retained post-injury. Interestingly, uninjured IVDs adjacent to the site of
injury were disrupted in Panx3-/- mice but remained healthy in WT mice. These studies
suggest a role for Panx3 in mediating adaptive AF cellular responses to acute mechanical
stress.

Keywords: Pannexin 3, intervertebral disc, degeneration, needle puncture injury, aging,
hypertrophy, mechanical loading, mechanical stress, annulus fibrosus cells, transgenic
mice
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CHAPTER 1:
INTRODUCTION
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1.1.

The Problem is Back Pain

Back pain continues to be a major problem worldwide1–3. The 2016 Global Burden of
Disease study, which assessed 195 countries and territories, identified back pain as the
single leading cause of years lived with disability in mid- to high-income countries, and
within the top 5 causes of disability in countries with a low-income economy3. In Canada,
back pain is reported as the most common cause of chronic pain in individuals aged 12-44,
and is estimated to impact more than 80% of North Americans at some point throughout
their lifetime4–8. This debilitating condition poses a significant burden on affected
individuals, the healthcare system and society2,5,9. Individuals impacted by chronic back
pain report feeling a loss of independence, social isolation, a fear of having to leave work
and subsequent financial insecurity, in addition to hopelessness and disappointment with
current treatment options10. On a societal level, back pain is associated with substantial
costs directly to the healthcare system, as well as indirect costs from decreased productivity
and absences from work9,11. In the US alone, the annual economic burden of back pain is
predicted to exceed $100 billion11,12. Although back pain affects individuals at all ages,
the impact on quality of life is much greater in the older population7. As such, the societal
burden of back pain is only expected to rise as the population ages2.
Back pain can originate from several anatomical structures of the spine such as muscles,
ligaments, vertebral bones, nerve roots, facet joints, and intervertebral discs (IVDs)13. Of
these, IVD degeneration is highly prevalent among individuals with back pain, contributing
to as many as 40% of all cases14–16. Despite efforts to improve management of back pain
associated with IVD degeneration, no disease-modifying treatments currently exist. The
goal of treatment for IVD degeneration is to both eliminate painful symptoms and restore
tissue function, however, current treatment options are limited to symptomatic relief17–19.
Without the ability to restore disc structure and function, IVDs at adjacent spinal levels
may become more susceptible to degeneration, furthering the pain and disability
experienced by the patient20,21. Our inability to effectively treat IVD degeneration is largely
due to an incomplete understanding of the molecular processes that regulate IVD
development, function, and disease.
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1.2.

The Intervertebral Disc

The IVD is a fibrocartilaginous structure that forms the joints of the spine (Fig. 1.1A).
Located between adjacent vertebral bodies, it functions to absorb mechanical loads along
the vertebral column and to provide the spine with stability and flexibility22,23. The IVD is
formed by three anatomically distinct tissues: a central gel-like nucleus pulposus (NP)
contained by the surrounding annulus fibrosus (AF), both of which are interposed between
the cartilaginous endplates (CEP) that anchor the IVD to adjacent vertebrae. Each tissue
contains a unique cell population responsible for the synthesis of its extracellular matrix
(ECM), which dictates the tissue’s mechanical properties and function22–24. Overall IVD
function is dependent on the coordinated roles of its composite tissues22.
The Nucleus Pulposus
Made up of 70-90% water, the NP is an aneural, avascular gelatinous tissue forming the
core of the IVD, with structural components consisting predominantly of collagen type II
and proteoglycans23,24. Several types of proteoglycans can be detected in the healthy NP,
including biglycan, decorin and versican; however, aggrecan is by far the most prevalent25–
27

. An important characteristic of these proteoglycans is their covalently linked

glycosaminoglycan (GAG) side chains, which for aggrecan include keratan and
chondroitin sulfates24. These sulfated side chains impart a high density of anionic charges
responsible for the tissue’s ability to imbibe water24,28. Additionally, aggrecan molecules
bind hyaluronan to form large proteoglycan aggregates27,29. This interaction with
hyaluronan limits the diffusion of aggrecan within the NP matrix, ensuring uniform
distributions of loads across the tissue30. In addition to the rich aggrecan content, another
important contributor to NP tissue architecture is the fibrillar protein, collagen type II29.
The collagen fibrils within the NP are randomly arranged, creating a three-dimensional
meshwork that supports both the proteoglycan and resident cell populations23,24.
Similar to other connective tissues, the ECM constitutes the bulk of the NP29. Nonetheless,
the cells of the NP play a crucial role in tissue maintenance and repair, as well as mediating
responses to changes in the IVD microenvironment. The NP has two main cell types:
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A)

B)
Nucleus
Pulposus (NP)

AF

Annulus
Fibrosus (AF)

Cartilaginous
Endplate (CEP)

NP

⍺

Alternating
fiber direction

Figure 1.1. Schematic illustration depicting intervertebral disc (IVD) structure.
A) IVDs are located between adjacent vertebral bodies and are composed of three
anatomically distinct tissues: a central gel-like nucleus pulposus (NP), the surrounding
annulus fibrosus (AF), and cartilaginous endplates (CEP) that line the surfaces of superior
and inferior vertebral bodies (schematic courtesy of Dale Fournier) B) The gelatinous
matrix of the NP is encapsulated by the highly organized, concentric lamellar structure of
the AF. Collagen fibers within each lamella are arranged in parallel at an angle of
inclination that alternates between adjacent lamellae (modified from Smith et al., 201117;
included in this thesis under terms of the Creative Commons Attribution Non-Commercial
Share Alike License).

5

notochord cells and chondrocyte-like cells31. The notochord cells are large, vacuolated cells
highly abundant in the early developing IVD31,32. In humans, this population of cells begins
to decline shortly after birth and continues to do so into early adolescence until they are no
longer detectable32–34. Interestingly, the dramatic reduction in notochord cells coincides
with the onset of early degenerative changes in the IVD, suggesting an important role for
this cell population in maintaining NP homeostasis32,34,35. As notochord cells disappear, the
NP becomes instead populated with the much smaller chondrocyte-like cells, which
continue to maintain the tissue matrix throughout life17,26,36. While initial debate in the field
questioned the origin of this cell population, fate mapping studies have revealed that, at
least in mice, both notochord and chondrocyte-like cells are derived from the embryonic
notochord37,38.
Functionally, the NP is responsible for absorbing compressive loads between adjacent
vertebrae23. Given its matrix structure, composition, and importantly, its substantial water
content, the NP is well equipped to take on this role. The high osmotic potential created by
the rich proteoglycan content enables the NP to retain large quantities of water 22,39–41. This
in turn contributes to the hydrostatic properties of the tissue, allowing it to resist
compression during loading24,39,42. Importantly, the compressive strength of the NP is
dependent on radial forces being supported by the surrounding ring structure of the AF24,43.
The Annulus Fibrosus
Similar to the NP, the AF is primarily made up of water, collagens and proteoglycans;
however, the relative proportions of these ECM components differ between the tissues23.
Specifically, the AF is a fibrous tissue with collagens forming the largest component of its
dry weight, followed by proteoglycans23,29. The most distinguishable characteristic of this
tissue is the structural arrangement of its collagen network. The AF is arranged into 15-25
concentric lamellae of collagen bundles running in parallel24,44. Collagen fibers are oriented
at an approximate 30° angle from the transverse plane, and alternate in direction with each
subsequent lamella (Fig. 1.1B)43,45. This arrangement creates an angle-ply structure
responsible for the tissue’s tensile strength39,45,46. Separating adjacent lamellae is an interlamellar matrix occupied by the large aggregating proteoglycans aggrecan and versican, in
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addition to lubricin and elastin, each playing an important role in overall tissue
mechanics23,47,48. The AF can be further divided into inner and outer regions
distinguishable by the composition of their ECM45. The lamellar structure of the outer AF
is predominantly made-up of tightly arranged bundles of collagen type I29,44. The cells
embedded within this region are described as fusiform, or fibroblast-like, in morphology
and typically extend parallel to collagen fibers within the lamellae49,50. The inner AF acts
as a transition zone between NP and AF tissues, and as such, contains a higher density of
collagen type II and widened inter-lamellar spaces rich in aggrecan29,51,52. The cells of the
inner AF are reportedly less abundant and more spherical in morphology compared to those
of the outer AF49,50. Additionally, cells localized to the inter-lamellar spaces can be found
throughout the AF and are described as having a disc-shaped appearance50. These
differences in ECM constituents between the inner and outer region are thought to be
functionally related to variations in the loading environment across the tissue45,52.
As described above, the fibrous rings of the AF support the radial forces exerted by the
pressurized NP, in addition to permitting bending and twisting motions of the spine22,45.
Both functions require the tissue to resist significant tensile loading that is dependent on
the structural arrangement of its collagen network39. Furthermore, the aggrecan-rich interlamellar matrix of the inner AF allows the tissue to withstand additional compressive
loading23,42,43. Another structural feature essential in enabling the AF to resist these tensile
loads is its anchoring and integration into the underlying vertebral bone, which is believed
to be mediated by collagen fibers first passing through the adjacent CEP53,54.
The Cartilaginous Endplates
The CEP is a thin layer of hyaline cartilage that lines the superior and inferior surfaces of
vertebral bodies55. As such, its ECM is rich in collagen type II and proteoglycans, and is
populated by chondrocytes23. While being an arguably understudied component of the
IVD, the CEP is integral to maintaining IVD homeostasis. Functionally, the CEP plays
three key roles. Firstly, it acts as a barrier to contain NP tissue within its defined
boundary23,24. Secondly, it supports the distribution of loads from the IVD across the
surfaces of adjacent vertebral bodies23,56. And thirdly, the CEP acts as a semi-permeable
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surface for nutrient diffusion into the primarily avascular IVD55. While the outer AF is
vascularized, the primary source of nutrients to the inner AF and NP comes from diffusion
of small molecules, such as oxygen and glucose, across the CEP from the underlying
vertebral bone55,57. As a consequence of aging, the CEP can become increasingly calcified
such that it effectively inhibits the diffusion of nutrients to the IVD55,57. This process is
thought to contribute to the pathobiology of age-associated IVD degeneration55,57.
1.3.

Mechanobiology of the IVD

Like other musculoskeletal tissues, the IVD is sensitive to its mechanical environment and
depends on mechanical loading for the maintenance of its structural integrity42. Due to
surrounding ligaments and musculature, the IVD is never truly unloaded but rather exposed
to a constant basal level of mechanical stimulation known as preload43. Additional
mechanical stresses are experienced as a result of daily living, from simply supporting the
weight of the body when standing to enduring dynamic forms of loading while walking or
running. Cells embedded within IVD tissues are able to respond to these mechanical stimuli
to elicit changes in gene expression and protein function that allow the tissue to adapt to
mechanical demands22,42. Previous research has suggested an optimal range of mechanical
loading, or a physiological zone, that is necessary for matrix synthesis and tissue
homeostasis; however, loads experienced outside of this range have been shown to have
deleterious effects on tissue structure39,58,59.
Mechanotransduction in IVD Cells
Mechanotransduction is described as a process initiated by cell recognition of mechanical
stresses within the tissue matrix42. Once the cell senses these mechanical cues, it is able to
convert them into biochemical signals that then elicit biological responses42. It is worth
noting that not only are IVD cells responding to stresses that arise in the pericellular
environment, but the cells themselves are physically impacted by the mechanical loads,
which result in cell deformation, cell membrane stretching and cell volume changes39.
While being an active area of interest in the field, the ways in which IVD cells sense
mechanical loads are still poorly understood. Many have speculated on mechanisms of
mechanosensation based off those described in related cell types such as chondrocytes,

8

including ion channel activation, integrin-associated signaling, as well as ligand-mediated
receptor tyrosine kinase and G protein-coupled receptor activity42,58,60,61. Some progress
has been made in studies working with IVD cells in vitro, which have identified MAPK,
nitric oxide and Ca2+ signaling as important mediators of mechanotransduction62–66. A
larger body of work on this topic has focused on characterizing changes to the ECM as a
result of different forms of mechanical loading.
Physiological Loads and Tissue Homeostasis
Cells of the IVD respond to a wide variety of stresses and strains, and the ways in which
they do so are dependent on both load and cell type39. Specifically, overall anabolic
responses are detected when the loading parameters are thought to mimic physiological
loading64,67–69. This has been previously defined as a range of magnitudes (0.2-0.8 MPa)
and frequencies (0.1-1.0 Hz) that promote tissue maintenance and do not induce matrix
repair or degeneration58. Within this physiological range of magnitudes and frequencies,
studies have demonstrated upregulation of proteoglycans, collagens and tissue inhibitor of
metalloproteinase-1 in the NP following dynamic compression and hydrostatic
pressure58,70–74. Studies using AF cells have focused on cyclic tensile strains and show
decreased expression of matrix degrading enzymes, suggesting an overall reduction in
matrix catabolism, when loading parameters fell within the physiological range68.
IVD Tissue Response to Aberrant Mechanical Load
While physiological mechanical loading supports IVD homeostasis, external loads can also
result in the cells experiencing local stresses that fall below or above this physiological
zone, shifting the metabolic activity from anabolic to catabolic59. Sources of these “nonphysiological” loads include immobilization or zero gravity, which put the IVD in a state
of underload. On the other end of the spectrum there is weightlifting and exposure to wholebody vibration, which exposes the IVD to supraphysiological levels of loading. In both
scenarios, the cells sense either an inappropriate magnitude, frequency, or duration of
loading, which can often have damaging effects to matrix integrity through increased
expression of catabolic mediators59. Aberrant mechanical loading of NP and AF cells has
been shown to cause an increase in expression of matrix degrading enzymes and pro-
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inflammatory cytokines, as well as increased cell death59,64,71,75–77. Additionally, due to the
interdependent nature of the IVD tissues, a loss of functional capacity in one part of the
IVD can cause unfavourable mechanical stresses to be transmitted to adjacent disc tissues.
For example, a loss in the ability of the NP to resist compression results in a redistribution
of compressive loads to the AF, creating an altered mechanical environment for the cells
of this tissue29,42,78. This increase in load-bearing by adjacent disc tissue can initiate the
switch from IVD anabolism to catabolism, a scenario that is well characterized in the
pathogenesis of IVD degeneration28.
1.4.

IVD Degeneration

IVD degeneration has been best defined by Adams and Roughley (2006) as “an aberrant,
cell-mediated response to progressive structural failure”28. It propagates through a cascade
of maladaptive cellular responses that contribute to deterioration of the tissue structure and
subsequent loss of tissue function28. Importantly, IVD degeneration is multifactorial in
nature, with numerous risk factors contributing to a weakened tissue that is susceptible to
damage28.
1.4.1. Risk Factors
The literature emphasizes several risk factors for IVD degeneration, including age, tobacco
use, body weight, lack of exercise, occupational exposure to whole-body vibration,
repeated heavy lifting, and genetic predisposition79–82. Of these, genetic predisposition is
by far the greatest contributor, followed by age29,35,83,84. A number of genes have been
proposed to play a role in IVD degeneration, most of which have been identified through
a targeted gene approach85,86. Candidate genes predominantly encode proteins which
regulate ECM structure and turnover, including aggrecan, collagen type IX, vitamin D
receptor, and matrix metalloproteinase-3 (MMP-3)86–91. Aggrecan polymorphisms appear
to affect the number of GAG binding sites and consequently reduce the hydrophilic
properties of the IVD87. Collagen type IX, a fibril-associated collagen thought to support
the collagen type II network of the disc, and vitamin D receptor, an important mediator of
bone homeostasis, both have sequence variations which have been linked to IVD
degeneration88–90. Additionally, MMP-3, a matrix degrading enzyme, has a common
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polymorphism in the promoter region causing elevated gene expression, thus contributing
to matrix breakdown and susceptibility to IVD degeneration86,91. Importantly, and
consistent with osteoarthritis (OA), IVD degeneration is thought to be polygenic, meaning
that it is likely the combination of polymorphisms in several genes that contribute to the
development of IVD degeneration85,92,93. IVD aging is another prominent risk factor and is
associated with decreased tissue hydration, disrupted matrix turnover, and impaired
nutrient transport due to calcification of the CEP, all of which can contribute to a weakened
IVD structure28,29,94.
1.4.2. Pathogenesis
The pathogenesis of IVD degeneration is described as a loss of balance between anabolic
and catabolic regulation, which typically presents as increased matrix degradation coupled
with abnormal matrix synthesis17,86,95. Degenerated IVD tissues show increased expression
of matrix degrading enzymes, most notably those of the MMP and ‘a disintegrin and
metalloproteinase with thrombospondin motifs’ (ADAMTS) families95. MMP- 1, 3, 7 and
13 have all been detected in degenerated IVDs at levels greater than those of nondegenerated tissues96,97. Collectively, these MMPs are capable of breaking down major
ECM components of the IVD, including collagens type I and II, and non-collagenous
matrix proteins such as fibronectin and aggrecan96,97. Several ADAMTS proteins are also
upregulated in IVD degeneration, including ADAMTS- 4 and 596,98. These are aggrecan
cleaving enzymes whose activity has been found to contribute to the accumulation of
fragmented proteoglycans in degenerated IVD tissues, most notably in the NP98. These
enzymes are also detected in healthy tissue and play an important role in adaptive tissue
remodeling95; however, tissue integrity is compromised when catabolic activity is not
appropriately coupled with an anabolic response. ECM degradation in IVD degeneration
is instead coupled with abnormal matrix synthesis86,95. The collagen type II network
characteristic of the NP and inner AF becomes gradually replaced with collagen type I,
creating an increasingly fibrous matrix99. Additionally, aggrecan expression in the NP is
downregulated100. This, together with the increase in enzyme-mediated aggrecan
degradation, results in a substantial loss of tissue hydration and impaired ability to resist
compressive forces29,100. Consequently, these loads are transferred to the surrounding AF,
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imposing aberrant mechanical stresses on the tissue and cells100. The AF cells attempt to
compensate by initially increasing proteoglycan synthesis101,102; however, the sustained
abnormal mechanical loads eventually cause further deterioration of the tissue lamellar
structure and, in advanced cases, may result in radial tissue tears and NP herniation17,102.
Inflammatory cytokines have also been implicated in the pathogenesis of IVD
degeneration, most notably the pro-inflammatory cytokines interleukin-1 (IL-1) and
tumour necrosis factor-alpha (TNF-a)103,104. IL-1a and b are reportedly produced by the
cells of the NP and inner AF, and both have been shown to increase in expression with
degeneration103. Additionally, these cytokines mediate catabolic responses characteristic
of IVD degeneration by activating intracellular pathways that result in the upregulation of
MMP-3, MMP-13, ADAMTS-4, and the downregulation of aggrecan and collagen types I
and II103. TNF-a mediated signaling has also been shown to upregulate MMP-1, 3 and 13,
as well as ADAMTS-4 and 5, in cultured NP cells, and is itself upregulated in
degeneration105,106. TNF-a is also reported to play a role in the sensation of pain following
NP herniation, evidenced by the reduction in pain behaviours detected in a rat model of
disc herniation following treatment with a TNF-a inhibitor107. Additionally, high levels of
TNF-a are detected in herniated NP tissues and are thought to contribute, at least in part,
to the irritation of nerve roots108. Given the ingrowth of nerve fibers detected in degenerated
tissues, researchers have suggested a role for TNF-a as a potential mediator of pain
associated with IVD degeneration86,109.
Additional hallmarks of advanced IVD degeneration include vascular and, as described
above, neural ingrowth110,111. Innervation of the healthy IVD is typically limited to the
outer 1/3 of the AF; however, there is evidence of nerve ingrowth associated with IVD
degeneration which may contribute to discogenic pain110. Innervation was also often
accompanied by blood vessel ingrowth into the inner regions of the IVD, which may
facilitate infiltration of additional inflammatory cytokines into the degenerated IVD
tissue111.
The question of what precedes these cell-mediated catabolic responses of IVD
degeneration was addressed by Adams and Roughley (2006)28. Typically, a combination
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of risk factors first contribute to reduced tissue strength; for example, genetic
predisposition

combined

with

age-associated

nutrient

transport

impairment28.

Consequently, minor insults to the tissue can initiate significant structural disruptions28.
The cells of the IVD act to elicit, presumably, a repair response; however, abnormal
mechanical stresses instead promote expression of catabolic mediators that only further the
structural deterioration of the tissue28. It is easy to see how such events can lead to a
downward spiral resulting in the structural and functional failure characteristic of IVD
degeneration.
1.5.

Animal Models to Study IVD Degeneration

Due to limited availability and access to human tissues, particularly healthy IVD tissues or
tissues representative of early stage degeneration, animal models have been used to study
the pathobiology of IVD degeneration112. Commonly used large animal models include
cow, pig, sheep, goat, and dog113. The IVDs of larger animals share similarities in size and
structure with human IVD tissues and, in the case of sheep, have been shown to have
comparable spine biomechanics despite being a quadrupedal animal113,114. However, these
large animal models pose certain challenges, including housing costs, length of gestational
period, as well as lifespan. Mouse models are not only more manageable in terms of size,
lifespan, and cost, but they also permit genetic manipulation allowing for the investigation
of specific genes in the context of IVD function and disease. While much smaller in size,
the murine IVD is similar in structure and has been shown to best model human IVD
geometry in terms of the relative disc height, width, and proportional NP area115.
Additionally, murine IVD biomechanics measured by axial compression and torsion are
comparable to those of human lumbar IVDs when normalized for disc height116–118. The
fact that mice are quadrupedal is often accompanied by the assumption that loads
experienced in human IVDs are much larger than those in mice. However, the contraction
of surrounding musculature and tension generated across spinal ligaments required to
stabilize the spine in the horizontal plane actually impose substantial loads across the
murine spine112,119. It has therefore been suggested that the intradiscal pressure of the
murine IVD, due to substantial mechanical preload, is similar to loads experienced by IVDs
of the vertical human spine112,113,119. Accordingly, mouse models have been commonly
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used in this field to investigate hypotheses related to IVD biology, function and
degeneration.
1.5.1. Age-Associated IVD Degeneration in Mice
In humans, dramatic changes in tissue structure characteristic of IVD degeneration are
associated with increasing age35. Similar structural deterioration can be detected
histologically in aging mice120. A histological analysis of aging wild-type (WT) C57BL/6
mice provided evidence of spontaneous IVD degeneration as early as 14 months-of-age,
with severity of structural damage progressing with increasing age120. Due to the slow onset
of degenerative changes in this model, it can be useful in studying the natural progression
of IVD degeneration and associated changes in tissue morphology120. Similar to humans,
and likely a result of the multifactorial nature of naturally occurring IVD degeneration,
aging models are often associated with variability in terms of the age of onset as well as
severity of degeneration35,112,120.
1.5.2. Genetically Modified Mouse Models
A major advantage of mouse models is the ability to manipulate their genome. Advances
in the field of genetic engineering have facilitated the use of genetically modified mice to
investigate the function of a particular gene of interest121. A commonly used approach
involves the Cre/loxP recombinase system for targeted gene deletion, which relies on Cremediated excision of gene sequences flanked by loxP sites121,122. This technique can be
used to study whole-body loss of gene expression when Cre recombinase expression is
driven by a constitutive promoter123. Additionally, this system is also used for conditional
gene ablation, allowing researchers to investigate the role of a gene in a specific tissue type.
In these studies, Cre recombinase expression is regulated by a tissue-specific promoter,
limiting the excision of gene sequences flanked by loxP sites to tissues in which that
promoter is active122. A variety of studies using both whole-body and tissue-specific
knockouts have been conducted in the IVD and have provided valuable insight into the
specific genes involved in regulating tissue development, function and disease. Some
examples include work by Bedore et al., which demonstrated the important role of the
matricellular protein CCN2 in IVD development, where gene deletion in notochord-
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derived tissues (NP tissues) resulted in disrupted IVD formation and accelerated ageassociated degeneration124. In addition, whole-body loss of biglycan125, the SPARC
matricellular protein126, and collagen type IX127 all show accelerated IVD degeneration
compared to age-matched WT mice, highlighting the important role of these proteins in
maintaining IVD homeostasis.
1.5.3. Injury Models of IVD Degeneration: AF Needle Puncture
Injury models of IVD degeneration allow for the reproducible and timed induction of
degenerative changes in the IVD113. These models primarily function by causing acute
mechanical instability and altered loading across IVD tissues, which induce progressive
tissue deterioration consistent with IVD degeneration128,129. In studies using mice, a
commonly used method of inducing IVD injury is AF needle puncture, where a needle is
inserted through the AF into the central NP130. This induces immediate herniation of the
NP followed by depressurization of the tissue129. The loss of intradiscal pressure in the NP
compromises the IVD’s ability to withstand compression, thus transferring these loads to
adjacent tissues129. The aberrant mechanical stresses imposed on the remaining IVD tissues
elicit catabolic changes at the structural, biomechanical and molecular level characteristic
of degeneration128,129,131,132. Needle puncture injuries in mice are typically performed in the
lumbar or caudal spine. Accessing lumbar IVDs pose substantial technical challenges,
mainly due to the invasiveness of the approach necessary to access the tissue.
Consequently, researchers frequently use IVDs from the tail which are more easily
accessible and have comparable biomechanical and geometrical properties to human
lumbar IVDs when adjusting for tissue size115,117. As such, murine tail AF puncture is an
attractive model for studies investigating injury-induced IVD degeneration.
1.6. Pannexins
Pannexins (Panx) are a family of transmembrane glycoproteins that function by forming
large-pore channels at the plasma membrane133–135. This protein family is composed of
three members, Panx1, Panx2 and Panx3, all of which share a common topology consisting
of four transmembrane domains, two extracellular loops, a single intracellular loop, and
cytosolic amino and carboxyl termini (Fig. 1.2)134,136. In terms of polypeptide sequence,
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Figure 1.2. Schematic illustration of the pannexin family of transmembrane
glycoproteins.
Panx1, Panx2 and Panx3 are transmembrane glycoproteins with unique polypeptide
lengths but that share a common topology. All three pannexin family members exhibit Nlinked glycosylation in their extracellular loop. Panx1 has been shown to form a hexameric
channel at the cell surface where it mediates the movement of ions and molecules between
the intracellular and extracellular space. While studies have yet to confirm the oligomer
structure of Panx3, it is also predicted to form a hexamer. NT: amino-terminus; EL:
extracellular loop; IL: intracellular loop; CT: carboxy-terminus; C: cysteine residue
(Penuela et al., 2013134; included in this thesis with permission, see Appendix B).
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Panx1 and Panx3 are most similar, with 59% of the amino acid sequence conserved
between the proteins135. Studies investigating pannexin channel formation suggest that
Panx1 proteins oligomerize to form a hexameric channel, while Panx2 likely forms a
heptamer or octomer137,138. While no oligomerization data is available for Panx3, it is also
predicted to form a hexameric channel given its sequence homology with Panx1134,137.
Additionally, these proteins exhibit N-linked glycosylation at distinct positions on their
extracellular loop135,139. The addition of these carbohydrate chains seem to dictate the
intracellular distribution of pannexins, as well as facilitate their trafficking to the cell
surface135,139. Protein glycosylation is also predicted to inhibit pannexins from docking to
form intercellular channels characteristic of connexin gap junctions135,139.
Of the three pannexin family members, Panx1 is the most researched, likely attributed to
its broad expression pattern. Varying levels of Panx1 have been reported in heart, brain,
placenta, lung, liver, skeletal muscle, kidney, spleen, thymus, prostate, testis, ovary, small
intestine, colon, skin, pancreas, blood endothelium, cochlea, and articular cartilage
136,140,141

. Panx2 expression was initially found to be limited to regions of the central

nervous system; however, recent studies now predict a more widespread expression pattern
than initially suggested136,142. Panx3 seems to have the most restrictive expression pattern
with varying levels reported in the skin, kidney, spleen, brain, Leydig cells, epididymis,
efferent ducts, skeletal muscle, cochlea135,136,140,143,144, as well as robust expression detected
in skeletal tissues including bone and cartilage136,145–147.
The pore size of pannexin channels is relatively large, permitting passage of molecules up
to 1 kDa in size133. This translates to over 35, 000 molecules with the potential to pass
through these channels, the vast majority of which have yet to be identified133. ATP is
possibly the best characterized and is shown to pass through Panx1 channels following
activation by mechanical stress, depolarization of the cell membrane, elevated intracellular
Ca2+ or extracellular K+, as well as caspase cleavage of the carboxyl terminus148–152.
Similarly, Panx3 has been shown to facilitate the release of ATP from Panx3-transfected
ATDC5 (chondrogenic cell line), C2C12 (myogenic cell line), and primary calvarial cells
and can also be activated by membrane depolarization or mechanical stimulation135,146,147.
In addition to its localization at the cell surface, Panx3 plays a functional role at the
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endoplasmic reticulum (ER) where it permits the movement of Ca2+ from the ER lumen
into the cytosol146.
Due to the widespread expression profile of pannexins, they are associated with a multitude
of physiological functions134. Through its function in ATP release, Panx1 is proposed to
play a role in stress-induced vasodilation153, cilia motility in the lungs154, suppression of
tumor growth155, and macrophage recruitment to apoptotic cells150, among others134.
Although fewer studies have investigated Panx2, recent work suggests it may be involved
in the timing of neuronal differentiation as well as pancreatic b-cell function and prevention
of b-cell apoptosis156,157. The expression of Panx3 is predominantly associated with
processes of cellular differentiation and plays an important role in development of bone,
cartilage145–147 and possibly skeletal muscle, although reports appear to be
conflicting144,158,159.
1.6.1. Panx3 in Musculoskeletal Tissues
As described above, Panx3 is abundantly expressed in tissues of the musculoskeletal
system including bone and cartilage146,147. In bone, Panx3 is detected in osteoprogenitor
cells and mature osteoblasts where its expression is functionally linked to osteoblast
differentiation146. Mechanistically, this is associated with Panx3-mediated ATP release at
the cell surface and subsequent purinergic receptor activation, as well as Panx3-mediated
Ca2+ release from the ER146,160. Both elicit the activation of a complex series of signaling
pathways that ultimately lead to transcription of osteogenic regulators including osterix
and alkaline phosphatase, as well as activation of p21 to promote cell cycle exit146,160.
Panx3 is also robustly expressed in the prehypertrophic zone of the developing cartilage
growth plate and plays an important role in chondrogenesis147. Specifically, Panx3
expression is associated with reduced chondrocyte proliferation and terminal
differentiation of hypertrophic chondrocytes145,147. These changes in cell phenotype have
been attributed to Panx3-mediated ATP release and subsequent decrease in intracellular
cAMP147. This, in turn, is suggested to silence the parathyroid/parathyroid hormone-related
peptide signaling pathway and downstream PKA/CREB activation to inhibit cell
proliferation and promote hypertrophic differentiation147. Furthermore, binding sites for
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runt-related transcription factor 2 (Runx2), an important mediator of chondrocyte
hypertrophy and osteoblast differentiation, have been found in the Panx3 promoter
sequence145, providing further evidence for its involvement in chondrogenic and
osteogenic differentiation. The role of Panx3 in skeletal muscle is less clear, with one study
demonstrating PANX3 protein expression in mouse, rat and human quadriceps tissue
lysates144, while others report undetectable levels of PANX3 protein in rat soleus, extensor
digitorum longus, and flexor digitorum brevis muscles158. A third group showed low basal
levels of Panx3 mRNA in cultured myotubes but that expression significantly increased
when myotubes were challenged with saturated fatty acids159.
1.6.2. Panx3 and Osteoarthritis
Initial work by our group demonstrated a fourfold increase in Panx3 expression detected
in cartilage isolated from osteoarthritic knee joints compared to healthy control cartilage
in rodent models141,161. This led to subsequent investigations into the role of Panx3 in the
progression of post-traumatic OA in mice141. To study the role of Panx3 in OA, Moon et
al. generated both cartilage-specific as well as whole-body Panx3 knockout (Panx3-/-)
mice141. Initial characterization of these mice demonstrated no overt abnormalities in
growth plate morphology, skeletal development or size of the mice (Fig. 1.3A-B)141. These,
along with age-matched WT mice, were subjected to destabilization of the medial meniscus
(DMM) surgery to induce OA in the knee141. Knee joints were assessed eight weeks
following surgery, and histological evaluation demonstrated that Panx3-/- mice were
protected from the development of OA (Fig. 1.3C)141. While knee joints from WT mice
displayed degenerative changes consistent with OA, including severe cartilage erosion,
loss of proteoglycan staining, and osteophyte formation, knee joints from Panx3-/- mice
showed only minimal proteoglycan loss in the articular cartilage141.
An important driver of the articular cartilage degeneration characteristic of OA is
chondrocyte hypertrophy, classically marked by an increase in cell size and the expression
of collagen type X162,163. Hypertrophic chondrocytes are normally found in the growth plate
where, in addition to promoting bone growth, they facilitate cartilage resorption prior to
the deposition of new bone163. As such, they express matrix degrading enzymes,
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Figure 1.3. Initial characterization of the Panx3-/- mouse model during skeletal
development and in post-traumatic osteoarthritis.
A) Representative sections of newborn tibia growth plates from WT and Panx3-/- mice
stained with safranin-O/fast green. No overt differences in the organization or relative
lengths of the different growth plate zones were detected between WT and Panx3-/- mice.
B) Photographs of skeletal preparations from WT and Panx3-/- mice at 21 days-of-age
stained with Alizarin Red/Alcian Blue. Similarly, no differences in the lengths of long
bones or overall skeletal size were detected between WT and Panx3-/- mice. C)
Representative sections of knee joints 8-weeks following destabilization of the medial
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meniscus (DMM) surgery stained with safranin-O/fast green. WT knee joints displayed
degenerative changes consistent with osteoarthritis, whereas Panx3-/- knee joints remained
relatively healthy following DMM surgery. Black arrowhead: cartilage erosion; yellow
arrowhead: proteoglycan loss; black star: osteophyte formation (modified from Moon et
al., 2015141; included in this thesis with permission, see Appendix B).
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particularly MMP13162–164. In osteoarthritic cartilage, there is an inappropriate induction of
chondrocyte hypertrophic differentiation and its associated catabolic markers162,163. Given
the role of Panx3 in promoting the transition from proliferative to hypertrophic
chondrocytes, it was suggested that Panx3 may promote tissue breakdown in OA cartilage
by mediating the differentiation of hypertrophic chondrocytes141. Importantly, this work
highlights the catabolic role for Panx3 in articular cartilage following joint destabilization.
Based on similarities between pathological process involved in OA and IVD degeneration,
we wondered whether Panx3 is also involved in the latter.
1.7. Project Rationale, Hypothesis, Objectives
1.7.1. Rationale
There are currently no disease-modifying treatments for IVD degeneration and associated
back pain. This is largely attributed to our incomplete understanding of the molecular
mechanisms that regulate IVD health or those that promote or become dysregulated in
disease. Panx3 is a mechanosensitive, channel-forming protein abundantly expressed in
skeletal tissue. Importantly, Panx3 has been implicated in the progression of post-traumatic
OA in mice, suggesting a catabolic role in mechanically stressed articular cartilage. In
addition to bone and cartilage, our group has recently demonstrated Panx3 expression in
the IVD. Microarray data from our lab suggests a tissue-specific expression pattern of
Panx3 in the disc, with approximately 29-fold greater expression detected in the AF
relative to the NP of 2-month-old mice. Despite evidence of Panx3 expression in the IVD,
its function in this tissue remains unknown. Given the established role of Panx3 in
regulating physiological and pathological processes in related musculoskeletal tissues, as
well as its mechanosensitive properties allowing it to respond to mechanical stresses in the
tissue matrix, this protein serves as an attractive candidate for study in the IVD.
1.7.2. Hypothesis
Given its role in regulating pathological processes in related tissues such as articular
cartilage, we hypothesized that loss of Panx3 expression will delay and/or prevent the
accumulation of histologic and molecular markers of IVD degeneration in mice.
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1.7.3. Specific Objectives
Objective 1: To characterize Panx3 expression and localization in the IVD
Objective 2: To determine the role of Panx3 in age-associated IVD degeneration
Objective 3: To determine the role of Panx3 in an injury-induced model of IVD
degeneration
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CHAPTER 2:
METHODS
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2.1. Experimental animals and tissue harvesting
All mice used in this study were bred in-house. Whole-body Panx3-/- mice were previously
generated through deletion of the second exon in the Panx3 coding sequence141. The Panx3/-

colony was maintained by either crossing homozygous null mice (Panx3-/-) or

hemizygous mice (Panx3+/-), and C57BL/6 mice were independently bred to generate agematched controls. Polymerase chain reaction (PCR) genotyping was used to confirm
homozygous deletion of Panx3, as previously described141. Mice were housed in standard
cages and maintained on a 12-hour light/dark cycle, with rodent chow and water available
ad libitum. Mice were euthanized at 2, 3.5, 6, 12, 18 or 24 months-of-age by CO2
asphyxiation or lethal injection of sodium pentobarbital. Following euthanasia, intact
lumbar (L1- sacral (S)1) and caudal (Co5-Co12) spines were harvested for histological and
immunohistochemical analyses. Intact thoracic (T5-T13) and lumbar (L1-L6) IVDs
inclusive of NP, AF and CEP were microdissected from adjacent vertebral bones for
subsequent gene and protein expression analyses. In a subset of mice, intact thoracic and/or
lumbar IVDs were further dissected to isolate AF tissues for gene and protein expression
analyses. All procedures were conducted in accordance with the policies and guidelines set
forth by the Canadian Council on Animal Care and approved by the Animal Use
Subcommittee of Western University, London, ON (protocols 2017-154 and 2015-031,
Appendix C).
2.2. Percutaneous AF needle puncture procedure
To induce IVD degeneration, we optimized a percutaneous needle injury model of IVD
degeneration in the mouse caudal spine by modification of previous surgical
methods128,131,132,165–167. 2-month-old WT and Panx3-/- mice (n=6 per genotype) were
anesthetized using 1.75% isofluorane gas and dorsal view X-ray images were used to locate
caudal IVDs in reference to an electron-dense landmarking device made in-house (Fig.
3.10A). X-ray images were taken at a peak energy of 60 kVp and a tube current of 20 mA
using the PXM-20BT PLUS portable X-ray unit (United Radiology Systems Inc. Deerfield,
IL, USA). Using the landmarking tool, caudal IVDs 7/8 and 8/9 were identified and
mapped on the dorsal side of the tail (Fig. 3.10B). Using aseptic techniques, both caudal
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IVDs 7/8 and 8/9 were sequentially punctured with a 30-gauge needle inserted through the
skin into the centre of the disc. The depth of needle puncture was standardized using a 22gauge needle sleeve designed to expose 1.4 mm of the 30-gauge needle for puncture,
ensuring a puncture depth at 50-70% of the IVD width (Fig. 3.10C). The needle was held
in place for 45 s to standardize time of NP depressurization. The precision of the puncture
was confirmed with a lateral view X-ray (Fig. 3.10D). Uninjured caudal IVD 6/7 served as
the control. Following the procedure, mice were returned to normal cage activity and were
euthanized 48 h, 1 week or 6 weeks following disc puncture.
2.3. Western blotting
Intact IVDs and isolated AF tissues were harvested (8 IVDs pooled per mouse) from 2month-old WT mice (8 ± 2 weeks) for protein analysis and snap frozen immediately
following dissection. IVD tissues isolated from age-matched Panx3-/- mice served as the
negative control, and total protein isolated from human embryonic kidney (HEK) 293T
cells overexpressing mouse Panx3 (described by Penuela et al., 2007135) were used as a
positive control. Total protein was harvested from tissue samples following
homogenization (PRO250 tissue homogenizer, PRO Scientific) and sonication (Sonic
Dismembrator Model 100, Fisher Scientific) in Triton-based extraction buffer [1% Triton
X-100 (v/v), 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% deoxycholate (w/v), 0.1% SDS
(v/v), 2 mM EDTA, 500 mM NaF, 100 mM sodium orthovanadate, Mini EDTA-free
proteinase inhibitor tablet (Roche Diagnostics, Indianapolis, IN)]. Protein concentrations
were determined using the bicinchoninic acid (BCA) assay (Pierce, ThermoFisher
Scientific). Equal amounts of protein (16 µg) were separated by gel electrophoresis on a
10% sodium dodecyl sulfate-polyacrylamide gel and transferred to a nitrocellulose
membrane using the iBlot dry transfer system (Invitrogen). Membranes were blocked for
1.5 hours with 3% (w/v) bovine serum albumin (BSA) in phosphate buffer saline (PBS).
Immunodetection of Panx3 was performed using a custom-made, site-directed rabbit
polyclonal anti-Panx3 primary antibody135 diluted to 1:1,000 in 0.05% (v/v) Tween20 in
PBS. Membranes were incubated with the primary antibody overnight at 4ºC. Following
three washes, membranes were incubated with IRDye 800CW fluorophore-conjugated goat
anti-rabbit secondary antibody (LiCor, 925-32211) diluted 1:10,000 in 3% (w/v) BSA in
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0.05% (v/v) Tween20-PBS. Membranes were incubated with the secondary antibody for
45 min at room temperature prior to visualization using Odyssey LiCor infrared imaging
system. The GAPDH loading control was detected using a mouse monoclonal antiGAPDH primary antibody (Millipore Sigma, MAB374) diluted 1:5,000 in 0.05% (v/v)
Tween20-PBS, followed by incubation with IRDye 680RD fluorophore-conjugated goat
anti-mouse secondary antibody (LiCor, 925-68070) diluted 1:10,000 in 3% (w/v) BSA in
0.05% (v/v) Tween20-PBS. Panx3 expression was quantified using densitometry and
presented relative to that of GAPDH.
2.4. Gene expression analyses
Panx3-/- and WT IVD tissues (6-7 IVDs pooled per mouse) harvested for gene expression
analyses were placed in TRIzol (Life Technologies) immediately following dissection.
Samples were homogenized using the PRO250 tissue homogenizer, and total RNA
extracted according to the manufacturer’s protocol. RNA concentrations were determined
using a NanoDrop 2000 spectrophotometer (Thermo Scientific), followed by reverse
transcription of 350 ng of RNA/sample into cDNA using the iScript cDNA Synthesis Kit
(Bio-Rad). Gene expression was assessed by real-time qPCR using the Bio-Rad CFX384
system. All reactions were run in triplicate with a starting cDNA quantity of 140
ng/reaction other than those assessing pannexin expression which were run with 420
ng/reaction. Each reaction contained 470 nM of forward and reverse primers and 2 x
SsoFast EvaGreen Supermix (Bio-Rad). PCR primers were previously validated for
specificity and efficiency of amplication168–170 (sequences provided in Table 2.1). The PCR
followed a 2-step protocol with the following parameters: initial 2 min denature step at
95°C, 10 s denature step at 95°C followed by 30 s annealing/elongation step (see
temperatures listed in Table 2.1) repeated for 45 cycles, followed by a melt curve.
Transcript levels were quantified using the DDCT method, normalized for input based on
expression of the Ribosomal Protein S29 (Rps29) housekeeper and expressed relative to
age-matched WT controls. The following target genes were assessed: aggrecan (Acan),
versican (Vcan), collagen type I (Col1a1), collagen type II (Col2a1), Adamts4 and 5
(Adamts4 and Adamts5), MMP13 (Mmp13), Runx2 (Runx2), collagen type X (Col10a1),
Panx1 (Panx1) and Panx2 (Panx2). Panx1, Panx2 and Panx3 transcript levels were also
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assessed in WT IVD tissues at specific time points and quantified relative to a six-point
standard curve (1/5 serial dilution with initial input of 240 ng/µL) made from cDNA
generated from IVD tissues at postnatal day 28 (for Panx3 expression) or brain tissue (for
Panx1 and Panx2 expression).
Table 2.1 qPCR Primer Sequences
Gene
Symbol

Primer Sequence (5’ to 3’)

Annealing/Elongation
temperature

Acan

FWD – CTGGGATCTACCGCTGTGAAG
REV – GTGTGGAAATAGCTCTGTAGTGGAA

60 °C

Vcan

FWD – TTTTACCCGAGTTACCAGACTC
REV – GGAGTAGTTGTTACATCCGTTG

60 °C

Col1a1

FWD – CTGGCGGTTCAGGTCCAAT
REV – TCCAGGCAATCCAGGAGC

60 °C

Col2a1

FWD – GCACATCTGGTTTGGAGAGACC
REV – TAGCGGTGTTGGGAGCCA
FWD – CTTCTTCTTGTTGAGCTGGAACTC
REV – CTCTGTGGACCTCACTGTAGACT
FWD – ATGGCTTGGGTTTCAGGTTAGGGA
REV – TGGAGTGAAGGATGAGGGCAAACT

60 °C

FWD – GAGGAGGAGATCGTGTTTCCAG
REV – CAAACCCTCTACCTGCACCC
FWD – GGAGCGAGGCCATTTACAAC
REV – GCGTAGACAAGGTAGCCCACTTT
FWD – GGGACCCCAAGGACCTAAAG
REV – GCCCAACTAGACCTATCTCACCT
FWD – ACAGGCTGCCTTTGTGGATTCA
REV – GGGCAGGTACAGGAGTATG
FWD – TGGTACCCATCCTGCTGGT
REV – GGGTGAAGTTGTGCGGAGT
FWD – TTTCGCCCAGGAGTTCTCATC
REV – CCTGCCTGACACTGAAGTTG

60 °C

Mmp13
Runx2
Adamts4
Adamts5
Col10a1
Panx1
Panx2
Panx3

60 °C
60 °C

60 °C
60 °C
60 °C
60 °C
65 °C

2.5. Histological analyses
Panx3-/- and WT spines harvested for histological analyses were fixed overnight with 4%
(w/v) paraformaldehyde in PBS, followed by 7 days of decalcification with Shandon’s
TBD-2 (Thermo Scientific). Following standard histological processing, tissues were
embedded in paraffin and sectioned sagittally at a thickness of 5 µm. Mid-sagittal sections
of lumbar and caudal spines were deparaffinised and rehydrated as previously described124,
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followed by staining with 0.1% safranin-O/0.05% fast green for detection of sulfated GAG.
Serial sections of caudal spines were stained with Masson’s Trichrome for visualization of
collagens. Stained sections were imaged using a Leica DM1000 microscope with Leica
Application Suite software. Safranin-O/fast green stained sections of the lumbar spine were
assessed for IVD degeneration using an established histopathological scoring system
modified to include Part A (I) (excluding score 4: mineralized matrix in NP), Part B (I) and
Part C171. Briefly, scores were assigned to the NP, AF and NP/AF boundary based on
criteria designed to assess gross morphological changes associated with degeneration in
mice. Scores assigned to individual IVD compartments were tallied for a total combined
score out of 9, with higher scores assigned to tissues presenting with a greater degree of
degeneration. Scores presented represent an average of 4-6 lumbar IVDs/mouse.
ImageJ (version 1.51s; National Institute of Health) was used to measure the average
lamellar width of AF tissues in caudal sections stained with Masson’s Trichrome. Lamellar
widths were defined as the distance between the inner edges of adjacent lamellae (includes
lamella, inter-lamellar matrix and associated cells), and measurements were made at an
angle perpendicular to the orientation of each lamella. Measurements were taken for all
lamellae on the side of needle puncture and averaged for each IVD. Two punctured IVDs
were assessed for each mouse.
2.6. Immunohistochemistry
Sagittal sections of lumbar and caudal spines were used for immunohistochemical
analyses. Antigen retrieval was performed at room temperature in 0.1% (v/v) Triton-X
followed by incubation in 3% (v/v) hydrogen peroxide in methanol to inhibit endogenous
peroxidase activity. Slides were blocked in species-specific serum (5%) in PBS for 30 min
at room temperature, followed by primary antibody incubation in a humidity chamber
overnight at 4°C. Primary antibodies were diluted in blocking solution as follows: rabbit
polyclonal anti-COL10 antibody (abcam, ab58632) diluted 1:750; rabbit polyclonal antiMMP13 antibody (Proteintech, 18165-1-AP) diluted 1:200; rabbit polyclonal anti-RUNX2
antibody (Novus Biologicals, NBP1-77461) diluted 1:100; goat polyclonal anti-SOX9
antibody (R&D Systems, AF3075) diluted 1:300. As a negative control, slides were

29

incubated overnight in blocking solution in the absence of primary antibody. IgG isotype
controls were included for MMP13 and RUNX2 immunostaining. Slides were incubated
in secondary antibody for 1 h at room temperature. Secondary antibodies were diluted in
PBS as follows: goat anti-rabbit (R&D Systems, HAF008) diluted 1:100 for RUNX2
immunodetection; goat anti-rabbit (SantaCruz, sc-2004) diluted 1:250 for MMP13 and
COL10 immunodetection; donkey anti-goat (R&D Systems, AF109) diluted 1:200 for
SOX9 immunodetection. All secondary antibodies were conjugated to horseradish
peroxidase. Immunopositive staining was visualized following incubation with
diaminobenzidine substrate (Dako Omnis), followed by counterstaining with 0.5% methyl
green. Immunostaining was assessed in 4-6 IVDs/mouse.
2.7. Statistical analyses
Statistical analyses were performed using GraphPad Prism Software version 6.0c. Data
from qPCR analyses comparing pannexin gene expression across time points were assessed
using a one-way ANOVA followed by Tukey’s multiple comparison test. qPCR analyses
comparing gene expression between Panx3-/- and WT mice were assessed using a twotailed, unpaired t-test with Welch’s correction, followed by the ROUT outlier test using a
Q coefficient of 1%. Western blot analyses comparing protein expression between intact
IVD and AF-only tissues, as well comparison of average lamellar width measurements
between Panx3-/- and WT mice were evaluated by two-tailed, unpaired t-test.
Histopathological scores were compared between Panx3-/- and WT mice using a MannWhitney U nonparametric test. P < 0.05 were considered statistically significant.
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CHAPTER 3:
RESULTS
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3.1. Pannexin expression in the IVD
We first sought to quantify the expression of Panx3 in the IVD and examine changes
associated with age. WT mice were sacrificed at 2, 6, 12, 18, and 24 months-of-age and
intact thoracic IVDs were harvested for gene expression analysis using real-time qPCR. To
examine potential tissue-specific expression within the IVD, AF tissues were also isolated
from the IVDs of WT mice at 2 and 6 months-of-age for gene expression analysis. Panx3
gene expression was detected in IVD tissues at all time points assessed, with significantly
greater expression detected at 2 months-of-age compared to the 6, 12, 18, and 24-month
time points (Fig. 3.1A). No significant differences in Panx3 transcript levels in the IVD
were detected between 6, 12, 18, and 24-month time points. Moreover, we detected
significantly greater expression of Panx3 in the isolated AF tissues at 2 and 6 months-ofage compared to samples generated from whole IVDs at the corresponding time points
(Fig. 3.1B).
Given the redundancies in expression of pannexins in various tissues, including coexpression of Panx1 and Panx3 in articular cartilage135,141, we assessed Panx1 and Panx2
gene expression in IVD tissue samples from WT mice. Analysis of Panx1 gene expression
demonstrated similar transcript levels in whole IVD tissue from 2, 6, and 12-month-old
mice (Fig. 3.1C). Interestingly, there was significantly greater Panx1 expression detected
at both 18 and 24 months-of-age compared to the earlier time points. Panx2 gene
expression was assessed in the IVD tissue samples, however, transcription levels fell below
the detectable limit.
PANX3 protein expression was also assessed in IVD tissues from 2-month-old WT mice.
IVD tissues harvested from age-matched Panx3-/- mice served as the negative control and
total protein isolated from PANX3-overexpressing HEK293T cells was used as a positive
control. Western blot analysis revealed robust PANX3 protein expression in both the whole
IVD and isolated AF, with no evidence of PANX3 expression in knockout tissues (Fig.
3.1D). Densitometry showed no significant difference in PANX3 levels between samples
of total protein isolated from whole IVD and AF tissue alone, confirming strong PANX3
protein expression in the AF at 2 months-of-age (Fig. 3.1D).
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Figure 3.1. Characterization of pannexin expression in the murine IVD.
A) Real-time qPCR analysis of Panx3 gene expression in thoracic IVDs harvested from
WT mice at 2, 6, 12, 18, or 24 months-of-age. Panx3 transcription levels were significantly
higher in IVD tissues isolated at 2 months-of-age when compared to those from 6, 12, 18,
and 24-month-old mice. B) Analysis of Panx3 expression in the intact IVD (AF, NP and
CEP) versus AF tissues alone harvested from WT mice at 2 or 6 months-of-age. At both
the time points, there was significantly greater Panx3 expression in AF-only samples
compared to intact IVD. C) Analysis of Panx1 gene expression in thoracic IVDs harvested
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from aging WT mice. There were no significant differences in Panx1 expression levels
between the 2, 6, or 12-month time points; however, a significant upregulation was
detected at the 18 and 24-month time points. Gene transcript levels were determined
relative to a six-point standard curve, and data are presented as mean ± SD. Bars labelled
with the same letter are not significantly different based on p<0.05; one-way ANOVA
followed by Tukey’s post-hoc test (n=4-8 mice per group). D) Western blot analysis of
PANX3 protein expression in whole IVD or AF tissues from 2-month-old WT mice.
Protein harvested from Panx3-/- IVD tissues served as a negative control and PANX3overexpressing HEK293T cells served as a positive control. PANX3 protein was detected
in both the whole IVD and AF, with no significant difference in the level of expression
between the two. PANX3 expression was quantified using densitometry and presented
relative to that of GAPDH. Data represent mean ± SD (n=3).
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3.2. No overt differences in IVD tissue morphology between WT and Panx3-/- mice
over time
Using a whole-body Panx3-/- mouse model previously reported by our group141, we
investigated the role of Panx3 in age-associated IVD degeneration. WT and Panx3-/- mice
were aged to 6, 12, 18, or 24 months-of-age, and lumbar spines were harvested for
histopathological analysis. At 6 and 12 months-of-age, no differences were detected in the
histological appearance of lumbar IVDs from WT and Panx3-/- mice, with all tissues
appearing relatively healthy (Fig. 3.2A). As such, there were no significant differences in
histopathological scores between WT and Panx3-/- mice at these time points (Fig. 3.2B).
IVD tissues from 18-month-old mice showed early signs of IVD degeneration, including
disruptions in the lamellar organization at the NP-AF boundary (arrows) and GAG
accumulation in the inter-lamellar matrix in the inner AF contributing to increased lamellar
separation (arrowheads) (Fig. 3.2A). These histopathological changes were evident in both
the WT and Panx3-/- mice at this time point. In addition to the gross changes in tissue
organization, we detected changes in AF cell morphology in IVDs displaying early signs
of degeneration. Cells appeared larger and rounder than those in healthy AF tissues and
were often associated with increased pericellular GAG staining. Clusters of these enlarged
AF cells were detected in both WT and Panx3-/- mice at 18 months-of-age, but appeared to
be more pronounced in WT tissues (Fig. 3.2A). Degeneration progressed in IVD tissues
from mice at 24 months-of-age, with a loss of cellularity and increased matrix synthesis in
the NP, loss of a defined border between NP and AF, and increased inter-lamellar space
throughout the AF. Additionally, enlarged AF cells with a GAG-rich pericellular matrix
were detected throughout the AF (Fig. 3.2A). These morphological changes were evident
in both WT and Panx3-/- tissues at this time point. Histopathological scoring supports this
observation, with no significant differences detected between WT and Panx3-/degenerative scores at either 18 or 24 months-of-age (Fig. 3.2B).
3.3. No evidence of compensatory upregulation of Panx1 in Panx3-/- mice
In addition to Panx3, our data demonstrates Panx1 expression in the IVD, raising the
possibility of compensation among pannexin proteins in the Panx3 knockout mouse model.
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Figure 3.2. Effects of Panx3 deletion on age-associated IVD degeneration.
A) Representative mid-sagittal sections of lumbar IVDs stained with safranin-O/fast green
from 6, 12, 18, and 24-month-old WT and Panx3-/- mice. Histological evaluation showed
no overt differences in overall IVD morphology between WT and Panx3-/- mice, with both
groups showing early signs of degeneration at 18 and 24 months-of-age. B) IVD
degeneration was quantified using an established histopathological scoring system
developed to assess IVD health in mice. Scores were assigned to the NP, AF, and NP/AF
boundary, for a maximum total combined score of 9, with higher scores representing a
greater degree of degeneration. Histopathological scores demonstrated no significant
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differences in IVD degeneration between WT and Panx3-/- mice at 6, 12, 18, or 24 monthsof-age. Data are presented as mean ± SEM (6 months n=8 WT and 6 Panx3-/- mice; 12
months n=7 WT and 6 Panx3-/- mice; 18 months n=8 WT and 10 Panx3-/- mice; 24 months
n= 9 WT and 12 Panx3-/- mice; scores represent 4-6 IVDs/mouse). Arrows indicate
disruption in lamellar organization at the NP-AF boundary, arrowheads indicate increased
GAG staining in the inter-lamellar matrix.
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For example, Lohman et al. demonstrated a dramatic upregulation in PANX3 following
loss of Panx1 in the vascular endothelium and smooth muscle, tissues in which it is not
readily detectable172. To determine if compensation exists in the IVD in response to loss of
Panx3 expression, Panx1 and Panx2 expression was analyzed in IVD tissues from WT and
Panx3-/- mice at 6, 12, 18, and 24 months-of-age. No change in Panx1 gene expression was
detected between WT and Panx3-/- IVD tissue at any of the time points examined,
suggesting a lack of compensatory upregulation in the IVD in the absence of Panx3 (Fig.
3.3). Panx2 expression was assessed but was not reliably detectable in IVD tissues of WT
or Panx3-/- mice.
3.4. Loss of Panx3 is associated with altered expression of markers of IVD anabolism
and catabolism
To assess early changes in IVD health and degeneration, we quantified the expression of
markers of IVD anabolism and catabolism. Assessment of candidate ECM genes
demonstrated no significant differences in transcript levels of Acan, Vcan, Col1a1, or
Col2a1 between WT and Panx3-/- IVD tissues from mice at 6 or 12 months-of-age (Fig.
3.4). At the 18-month time point, Acan and Col1a1 expression were significantly
downregulated in IVDs from Panx3-/- mice relative to WT, while no differences in Vcan or
Col2a1 expression were detected (Fig. 3.4). No significant differences in the expression of
ECM genes were detected between WT and Panx3-/- IVD tissues from 24-month-old mice
(Fig. 3.4).
Next we investigated aggrecanase gene expression in the IVD, enzymes previously shown
to contribute to the loss of aggrecan characteristic of IVD degeneration96,98. At 6 monthsof-age, IVD tissues from Panx3-/- mice showed significantly reduced Adamts5 expression
compared to age-matched WT mice, while no differences in Adamts4 expression were
detected at this time point (Fig. 3.5). Neither Adamts4 nor Adamts5 expression were altered
between Panx3-/- and WT mice at 12, 18, or 24 months-of-age (Fig. 3.5).
Lastly, given the role of Panx3 in promoting hypertrophic differentiation in articular
cartilage147, we assessed the expression of classical markers of chondrocyte hypertrophy
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Figure 3.3. Quantification of Panx1 gene expression in Panx3-/- mice.
Real-time qPCR analysis of Panx1 expression in thoracic IVDs from 6, 12, 18, or 24month-old WT and Panx3-/- mice. Gene expression was determined by relative
quantification with values normalized for input using the Rps29 housekeeper and expressed
relative to age-matched WT controls. No significant difference in Panx1 expression was
detected between WT and Panx3-/- mice at any of the time points examined. Panx2
expression was also assessed, however, it was not reliably detected in the IVD. Data are
presented as mean ± SD (6 months n=8 WT and 7 Panx3-/- mice; 12 months n=7 WT and
6 Panx3-/- mice; 18 months n=4 WT and 5 Panx3-/- mice; 24 months n=5 per group).
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Figure 3.4. Effect of Panx3 deletion on the expression of ECM genes in the IVD.
Real-time qPCR analysis of gene expression in thoracic IVDs isolated from 6, 12, 18 or
24-month-old WT and Panx3-/- mice. Expression of Acan, Vcan, Col1a1, and Col2a1 was
determined by relative quantification with values normalized to that of the Rps29
housekeeper and expressed relative to age-matched WT controls. No significant
differences in the expression of candidate ECM genes were detected at 6, 12 or 24 monthsof-age. In 18-month-old mice, Col1a1 and Acan transcript levels showed a significant
decrease in IVD tissues from Panx3-/- mice relative to WT controls, while no significant
difference in Vcan or Col2a1 expression were detected at this time point. Data are presented
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Figure 3.5. Effects of Panx3 deletion on the expression of aggrecanase enzymes in the
IVD.
Real-time qPCR analysis of gene expression in thoracic IVDs isolated from 6, 12, 18, or
24-month-old WT and Panx3-/- mice. Expression of Adamts4 and Adamts5 was determined
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in the IVD. At 6 and 12 months-of-age, there were no significant differences in expression
of Mmp13, Runx2, or Col10a1 between IVD tissues from WT and Panx3-/- mice (Fig. 3.6).
Interestingly, at the 18-month time point, there was a significant downregulation in the
expression of Mmp13 and Runx2 in IVD tissues from Panx3-/- mice relative to WT, but no
differences in Col10a1 expression (Fig. 3.6). At 24 months-of-age, IVD tissues from WT
and Panx3-/- mice expressed similar levels of Mmp13, Runx2, and Col10a1 (Fig. 3.6).
3.5. Altered localization of hypertrophic chondrocyte markers in IVDs of Panx3-/mice
Given the downregulation we detected in the gene expression of hypertrophic markers in
Panx3-/- mice, we next assessed both the abundance and cell type-specific localization of
hypertrophic markers in lumbar IVDs from WT and Panx3-/- mice. COL10-positive
staining was detected in IVD tissues of both WT and Panx3-/- mice at 6, 12, 18, and 24
months-of-age. In 6-month-old mice, no overt differences in COL10 localization or
abundance were detected between WT and Panx3-/- mice; with both genotypes showing
positive staining localized to the outer AF (Fig. 3.7). While there were no overt differences
in abundance of COL10 staining in the AF at 12 months-of-age, we did note a subtle
difference in the staining pattern between WT and Panx3-/- mice, particularly at the CEPAF interface. This region is known to calcify with age and has been previously reported to
express collagen type X54. COL10 staining in this region was more consistently detected
in WT mice compared to Panx3-/- mice at the 12-month time point (Fig. 3.7). This trend in
localization was more pronounced in 18 month-old-mice, where COL10 staining along the
CEP-AF interface was detected more frequently in WT mice than in Panx3-/- mice (Fig.
3.7). Furthermore, COL10 staining in 18-month-old WT mice was detected in both the
inner and outer AF, whereas staining in Panx3-/- mice seemed to be predominantly
localized to the outer AF (Fig. 3.7). At the 24-month time point, COL10-positive staining
could be detected in both inner and outer AF regions, with no overt differences in
abundance or pattern of positive staining detected between WT and Panx3-/- mice (Fig.
3.7).
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Figure 3.6. Effects of Panx3 deletion on the expression of hypertrophic chondrocyte
markers in the IVD.
Real-time qPCR analysis of gene expression in thoracic IVDs isolated from 6, 12, 18 or
24-month-old WT and Panx3-/- mice. Expression of Mmp13, Runx2 and Col10a1 was
determined by relative quantification with values normalized to that of the Rps29
housekeeper and expressed relative to WT controls. In 18-month-old mice, Mmp13 and
Runx2 transcript levels showed a significant decrease in IVD tissues from Panx3-/- mice
relative to WT controls, while no significant difference in Col10a1 expression was
detected. No significant differences in gene expression were detected at 6, 12 or 24 monthsof-age in any of the candidate hypertrophic markers. Data are presented as mean ± SD (*,
p<0.05, Welch’s t-test; Mmp13 and Runx2: 6 months n=7 WT and 6 Panx3-/- mice; 12
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Figure 3.7. Effect of Panx3 deletion on COL10 localization in the IVD.
Representative images showing the immunohistochemical localization of COL10 protein
in mid-sagittal sections of lumbar IVDs from 6, 12, 18, or 24-month-old WT and Panx3-/mice. Sections were stained with anti-COL10 antibody and counterstained with methyl
green. No overt differences in COL10 abundance or localization were observed between
WT and Panx3-/- mice at 6 months-of-age. At both 12 and 18 months-of-age, differences
were detected in COL10 localization to the CEP-AF interface. WT mice at these time
points displayed more consistent staining in this AF sub-compartment relative to agematched Panx3-/- mice. No overt differences in abundance or pattern of COL10 staining
were detected between WT and Panx3-/- mice at 24 months-of-age. Black arrowheads
indicate the localization to the CEP-AF interface in 12 and 18-month-old mice. (n=5 mice
per group, 4-6 IVDs/mouse).
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Based on our gene expression analysis and characterization of the onset of IVD
degeneration, we assessed MMP13 and RUNX2 at the later time points. Neither the
abundance nor localization of MMP13 immunostaining appeared to differ between IVD
tissues from WT and Panx3-/- mice at either 18 or 24 months-of-age (Fig 3.8A). MMP13
positive staining was primarily detected in the outer AF in 18-month-old mice, and sparsely
detected across inner and outer AF regions in 24-month-old mice (Fig. 3.8A). Overall,
there seemed to be less MMP13-positive staining detected at 24 months-of-age compared
to 18 months-of-age (Fig. 3.8A). RUNX2 immunostaining was also detected in IVD tissues
of both WT and Panx3-/- mice at 18 and 24 months-of-age. In 18-month-old mice, RUNX2
staining was detected in both the inner and outer AF, with the highest density of positive
staining localized to the outer AF in both WT and Panx3-/- mice (Fig. 3.8B). At 24 monthsof-age, no distinct difference in RUNX2 localization were detected between WT and
Panx3-/- mice, however, staining appeared to be more abundant in WT AF tissues. Similar
to MMP13, there seemed to be less RUNX2-positive staining detected at 24 months-of-age
compared to 18 months-of-age (Fig. 3.8B).
In keeping with previous reports171,173, our study identified the presence of enlarged AF
cells in WT IVD tissues at 18 and 24 months-of-age, coincident with the accumulation of
histopathological degenerative changes. To determine if these cells phenotypically
resembled hypertrophic chondrocyte, we assessed the localization of COL10, MMP13, and
RUNX2 to these areas. While COL10, MMP13, and RUNX2 staining can be detected in
IVDs from WT mice at 18 months-of-age, which contain enlarged AF cells, surprisingly
these cells did not show immunoreactivity for markers of chondrocyte hypertrophy (Fig.
3.9). These findings suggest that enlarged AF cells associated with degenerative changes
in the IVD are distinct from classical hypertrophic chondrocytes.
3.6. Percutaneous needle puncture induces changes consistent with degeneration in
caudal IVDs
Needle puncture models of IVD degeneration are well established in the field as models of
acute IVD injury following NP depressurization128,131,132,165–167. For these studies, we
optimized a less invasive procedure using X-ray imaging to guide percutaneous needle
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Figure 3.8. Effect of Panx3 deletion on MMP13 and RUNX2 localization in the IVD.
A/B) Representative images showing the immunohistochemical localization of MMP13 or
RUNX2 protein in mid-sagittal sections of lumbar IVDs from 18 or 24-month-old WT and
Panx3-/- mice. A) Sections stained with anti-MMP13 antibody demonstrate no overt
differences in localization or relative amount of positive staining between WT and Panx3/-

mice at 18 or 24 months-of-age. B) Sections stained with anti-RUNX2 antibody

demonstrate no overt differences in the localization of positive staining between WT and
Panx3-/- mice at 18 or 24 months-of-age, however, staining appeared to be more abundant
in WT mice compared to Panx3-/- mice at 24 months-of-age. (n=5 mice per group, 4-6
IVDs/mouse).
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Figure 3.9. COL10, MMP13 or RUNX2 staining does not co-localize with enlarged
AF cells detected with age-associated IVD degeneration.
Serial sections of a representative WT lumbar IVD at 18 months-of-age stained with either
safranin-O/fast green or anti- COL10, MMP13 or RUNX2 antibody. Representative
section stained with safranin-O/fast green demonstrates the accumulation of enlarged AF
cells in early degenerative AF tissues. Serial sections used for immunolocalization
demonstrate the lack of co-localization between enlarged AF cells and COL10, MMP13 or
RUNX2-positive staining, suggesting that these cells are distinct from classical
hypertrophic chondrocytes. Arrowheads: representative enlarged AF cells.
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insertion for IVD puncture. Using an electron-dense measuring tool, we were able to
reliably locate the caudal IVDs in anesthetized mice, targeting caudal 7/8 and 8/9 for
puncture (Fig. 3.10A-D). Depth of needle insertion was consistently maintained within 5070% of IVD width by using the custom-made needle sleeve (Fig. 3.10C). This model of
acute IVD injury allows for longitudinal studies of IVD repair, with adjacent uninjured
caudal IVDs (i.e. caudal 6/7) serving as controls. Initial validation of this minimally
invasive procedure confirmed morphological changes in the IVD immediately following
puncture, with loss of tissue volume in the NP (due to herniation) evident 48 hours
following puncture (Fig. 3.10E). Caudal spines harvested one week after puncture
demonstrated hallmarks of fibrous NP repair post-injury (Fig. 3.10E).
3.7. Panx3-/- mice do not show degeneration-associated changes in the AF following
IVD injury
Using the percutaneous IVD puncture model, we investigated the role of Panx3 in injuryinduced IVD degeneration. WT and Panx3-/- mice were subject to caudal IVD needle
puncture. Mice were sacrificed 6-weeks following injury, and caudal IVDs were harvested
for histopathological analysis. In WT and Panx3-/- mice, the NP demonstrated the expected
hallmarks post-puncture, including a loss of cell density and increased matrix synthesis
compared to uninjured control IVD tissues (Fig. 3.11B). While IVD tissues from both WT
and Panx3-/- mice showed changes to AF structure associated with needle penetration, the
AF tissue architecture appeared to be better preserved in Panx3-/- IVDs compared to WT
(Fig. 3.11B). Interestingly, we detected a consistent accumulation of enlarged AF cells in
all IVDs of WT mice following puncture (12/12 punctured IVDs, 6/6 mice), but rarely
detected enlarged AF cells in IVDs from Panx3-/- mice (1/12 punctured IVDs, 1/6 mice;
Fig. 3.11B). These large, rounded cells were located throughout the AF as well as at the
NP/AF boundary, and appeared to contribute to the lamellar disorganization observed in
WT mice following puncture (i.e. increased inter-lamellar GAG accumulation).
To assess changes in matrix organization in the IVD following puncture, mid-sagittal
sections of caudal IVDs from mice injured at 2 months-of-age were stained with Masson’s
Trichrome. In uninjured control IVDs, the AF structure appears as tightly arranged
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Control (uninjured IVD)

48 hours following puncture

1 week following puncture

Figure 3.10. Injury-induced model of IVD degeneration using percutaneous IVD
puncture.
Dorsal (A: X-ray; B: photograph) and sagittal (D: X-ray) view of a 2-month-old C57BL/6
mouse undergoing tail puncture procedure. A) A dorsal X-ray is first taken to identify
caudal IVDs 7/8 and 8/9 for puncture. B) Using an electron dense measuring tool, the
location of the IVDs are mapped out on the mouse tail. C) A 30-gauge needle, guided by a
22-gauge sleeve (red bracket) to standardize depth of puncture, is then inserted through the
skin into the IVDs. D) A sagittal X-ray is taken to confirm IVD puncture. E) Mid-sagittal
sections of control (non-punctured) and injured caudal IVDs stained with safranin-O/fast
green demonstrate depressurization of the NP 48 hours following needle puncture, with
some evidence of cell proliferation and formation of fibrous tissue repair detected after one
week.
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Figure 3.11. Effects of Panx3 deletion on IVD degeneration following NP
depressurization in caudal IVDs.
A) Representative X-ray images of caudal IVDs 7/8 and 8/9 undergoing needle puncture.
B) Representative mid-sagittal sections of caudal IVDs from WT and Panx3-/- mice
harvested 6-weeks following needle puncture injury. Adjacent, uninjured caudal IVD 6/7
served as controls. Sections were stained with safranin-O/fast green. Both WT and Panx3/-

IVDs showed similar gross morphological changes following injury consistent with NP

herniation, including loss of cell density and increased matrix synthesis. While AF structure
was altered in both WT and Panx3-/- mice following injury, AF tissue architecture was
better persevered in Panx3-/- mice relative to WT. Enlarged AF cells were detected in WT
AF tissues (12/12 punctured IVDs, 6/6 mice; arrowheads), but rarely detected in Panx3-/tissues (1/12 punctured IVDs, 1/6 mice), and are associated with disorganization of the AF
following injury. Images representative of n=6 mice per group, 2 IVDs/mouse. Arrows:
needle puncture track.
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concentric collagen lamellae (Fig. 3.12A). AF tissues from WT mice following injury
display disruptions in the AF lamellar organization. The inner AF shows areas in which
the lamellar structure is reversed towards the NP, as well as regions of undefined lamellar
structure. Additionally, WT mice displayed discontinuity of the NP-AF boundary as well
as a more serpentine lamellar configuration throughout the AF (Fig. 3.12A). In Panx3-/mice, minor disruptions to the AF structure were detected following needle puncture;
however, overall, the AF maintains a highly organized collagen structure (Fig. 3.12A).
To better quantify the alterations in AF lamellar structure, we measured lamellar width
throughout the AF of IVDs from WT and Panx3-/- mice (defined as the width of both the
lamellae and inter-lamellar matrix). In IVDs that had undergone needle puncture, there was
a significant increase in average lamellar thickness detected in WT mice relative to Panx3/-

mice (Fig. 3.12B).

To investigate the effects of NP depressurization resulting from disc puncture on AF cell
function, we performed immunohistochemical analysis of SOX9, a well-characterized
marker of chondrogenic cell types. In uninjured control IVDs, SOX9-positive staining was
detected in the majority of cells throughout the NP and AF. Following injury there was a
reduction in SOX9 staining in NP tissues from both WT and Panx3-/- mice, likely
corresponding to the decrease in cellularity following NP herniation (Fig. 3.13). SOX9
staining was detected throughout the AF of both WT and Panx3-/- mice, as well as in the
cluster of cells adjacent to the outer AF, suggesting that these cells may be remnants of
herniated NP tissue (Fig. 3.13). Intriguingly, the enlarged AF cells identified in WT IVDs
following puncture stained positive for SOX9 (Fig. 3.13).
3.8. Loss of Panx3 accelerates degeneration in adjacent uninjured IVDs
While IVD puncture was limited to caudal IVDs 7/8 and 8/9, we noted changes to the IVD
morphology in adjacent, uninjured caudal IVD 9/10 from Panx3-/- mice. In WT mice,
uninjured IVDs appeared to be unaffected by adjacent IVD injury (Fig. 3.14). In contrast,
the IVD directly distal to the site of injury in Panx3-/- mice often showed signs of
accelerated NP degeneration, including increased matrix density and reduced cellularity
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Figure 3.12. Maintenance of AF lamellar structure in Panx3-/- mice following IVD
injury.
A) Representative mid-sagittal sections of caudal IVDs from WT and Panx3-/- mice
harvested 6-weeks following needle puncture injury. Adjacent, uninjured caudal IVDs
served as controls. Sections were stained with Masson’s Trichrome to visualize the ECM.
Following injury, WT mice showed disorganization of the inner AF, loss of distinct
boundary between AF and NP, and thicker lamellar structures throughout. In contrast,
Panx3-/- mice maintained a highly organized AF structure with tightly arranged concentric
lamellae. B) Using ImageJ software, lamellar width was measured throughout the AF of
WT and Panx3-/- IVDs, defined as the width of the lamellae and inter-lamellar matrix. In
IVDs that had undergone acute NP herniation, there was a significant increase in the
average lamellar thickness in WT mice relative to Panx3-/- mice. Data are presented as
mean ± SD (*, p<0.05; unpaired t-test; n=6 mice per group, 2 IVDs/mouse).
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Figure 3.13. Effect of Panx3 deletion on SOX9 protein expression and localization
following NP depressurization in caudal IVDs.
Representative images showing the immunohistochemical localization of SOX9 in midsagittal sections of caudal IVDs harvested 6-weeks following needle puncture injury from
WT and Panx3-/- mice. Adjacent, uninjured caudal IVDs served as controls. Sections were
immunostained with anti-SOX9 antibody and counterstained with methyl green. Uninjured
control IVDs demonstrate SOX9 staining throughout the IVD, including the NP, AF, and
CEP. In IVDs that had undergone needle puncture, there was a decrease in SOX9 staining
in both WT and Panx3-/- NP tissues relative to controls, likely corresponding to the decrease
in cellularity. Both WT and Panx3-/- mice showed SOX9 positive staining throughout the
AF. The enlarged AF cells identified in WT tissues stained positive for SOX9
(arrowheads). Images representative of n=6 mice per group, 2 IVDs/mouse. Arrow:
herniated NP cells
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Figure 3.14. Effects of Panx3 deletion on IVD morphology in motion segments directly
adjacent to punctured IVDs.
A) Representative X-ray images of caudal IVD 8/9 undergoing needle puncture injury.
Dotted red rectangle highlights caudal IVD 9/10 within the motion segment distal to the
site of injury. B) Representative mid-sagittal sections of uninjured caudal IVDs distal to
the punctured IVDs, harvested 6-weeks after injury and stained with safranin-O/fast green.
In WT mice, uninjured IVDs appear unaffected by the adjacent disc injury. In contrast,
uninjured IVDs adjacent to the site of injury in Panx3-/- mice showed signs of accelerated
NP degeneration, including decreased cellularity and increased proteoglycan staining
(black dotted rectangle). These morphological changes were seen exclusively on the side
of needle insertion in the adjacent punctured disc. Images representative of n=6 mice per
group.
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localized to the side of needle insertion in the adjacent injured disc (Fig. 3.14). These
degenerative changes to NP tissues were observed in 3/6 Panx3-/- mice and 0/6 WT mice.
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CHAPTER 4:
DISCUSSION
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Panx3 is a mechanosensitive, channel-forming protein implicated in diverse physiological
and pathological functions in musculoskeletal tissues. Previous research suggests that it
plays an important role in cartilage, mediating hypertrophic differentiation of chondrocytes
in the growth plate147 and contributing to the development of post-traumatic OA in articular
cartilage141. Microarray data from our group provided evidence for Panx3 expression in
the IVD, enriched in the AF compared to the NP. Given the catabolic role of Panx3 in
related cartilaginous tissues, this work set out to investigate the hypothesis that loss of
Panx3 expression would slow the progression of IVD degeneration in mice. Our studies
characterized the temporal expression of Panx3 in the IVD, as well as confirmed its tissuespecific expression pattern in IVD tissues. Additionally, we showed for the first time
PANX3 protein expression in the IVD. Using a whole-body Panx3 knockout mouse model,
we demonstrated that loss of Panx3 does not significantly impact the progression of ageassociated IVD degeneration, but appears to confer protection to the AF following acute
NP herniation in an injury-induced model of IVD degeneration. Furthermore, our work
suggests that expression of Panx3 in AF cells may be required for the adaptive cellular
response to altered mechanical load. Taken together, these data do not support our initial
hypothesis but instead highlight a complex, context-dependent role of Panx3 in the IVD.
Expression of at least one of the three pannexin family members can be detected in every
tissue-type of the body136,151. While the expression of Panx3 is well characterized in other
musculoskeletal tissues, our study is the first to report Panx3 expression in the IVD.
Specifically, our data demonstrates that Panx3 is expressed in the IVD throughout the
murine lifespan, with expression levels that appear to be temporally regulated. In tissues
such as bone and cartilage, expression of Panx3 is most often associated with time points
related to development, associated with its functional role in processes that mediate bone
development and growth145,168. This is in keeping with our data that suggests Panx3
expression is highest in younger mice and drops following skeletal maturity, perhaps
suggesting a role for Panx3 in processes related to IVD growth. Our analysis also supports
initial observations from microarray data showing greater Panx3 gene expression in AF
samples compared to samples generated from the intact IVD. It is likely that the lower
Panx3 expression detected in whole IVD samples is a result of AF transcript levels being
diluted out by the mRNA content of NP and CEP cells. Our western blot analysis however
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demonstrated similar PANX3 protein levels in whole IVD and AF-only samples. Given
that we standardized the total protein loaded for each sample, we had anticipated a similar
pattern to that observed for Panx3 gene expression. These findings suggest active posttranscriptional regulation of Panx3 in IVD tissues. Limitations in the size of murine IVDs,
and thus the ability to isolate and collect sufficiently concentrated protein samples from
individual disc tissues, has prevented our analysis from extending to isolated NP and CEP
tissues. Future studies with antibodies suitable for immunohistochemical analyses will
allow for a detailed comparative analysis of Panx3 expression in the AF, NP and CEP,
throughout IVD development and aging. Nevertheless, these experiments confirm that
Panx3 mRNA and protein is highly expressed in the AF.
In studying the role of Panx3 in the context of age-associated IVD degeneration, our results
suggest that loss of Panx3 does not significantly impact the progression of disc
degeneration in mice. Consistent with previously published work120, histological
evaluation of IVDs from WT mice revealed signs of increasing degeneration corresponding
to increased age. Unexpectedly, these morphological changes were also observed in the
IVD of Panx3-/- mice, with no evidence of delayed or accelerated degeneration. Previous
research has established the potential for functional compensation between pannexin
family members. Studies in skin demonstrated significantly greater Panx3 expression in
Panx1 knockout mice174, a cellular response also observed in vascular endothelial and
smooth muscle cells following Panx1 deletion172. Given that we demonstrated Panx1
expression in the IVD, with increased expression associated with advanced age, we
assessed whether the absence of overt phenotype in Panx3-/- mice may be a consequence
of compensation in the expression of other pannexin proteins. Our quantification of Panx1
and Panx2 expression however revealed no upregulation in Panx3-/- mice. It is important
to acknowledge that increases in endogenous Panx1 activity in Panx3-/- mice remain a
possibility.
Although no gross morphological changes were detected between Panx3-/- and WT mice,
our analyses did detect changes that may suggest a minor protective role for the loss of
Panx3 within the cellular microenvironment. ECM genes Acan and Col1a1 were
downregulated in Panx3-/- mice at 18 months-of-age, which interestingly, coincides with
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the onset of degenerative changes in the IVD. Aggrecan is essential in maintaining proper
IVD structure and function, and loss of aggrecan from the NP is a hallmark of IVD
degeneration29,100,175. However, in the AF, upregulation of both mRNA and protein levels
of aggrecan has been associated with early degeneration, presumably an adaptive response
in the AF to the loss of NP functional capacity to resist compression101. While being the
predominant collagen type of the AF, increased collagen type I expression is also a wellestablished hallmark of IVD degeneration contributing to NP matrix fibrosis28,61. Given
that our gene expression analysis is limited to intact IVD samples, we are unable to localize
these changes in gene expression within specific IVD compartments, and thus cannot
specifically conclude if these changes represent anabolic or catabolic effects.
Interestingly, our studies also demonstrated a downregulation in Runx2 and Mmp13
expression in IVD tissues from Panx3-/- mice, genes which are well-characterized in the
context of chondrocyte hypertrophy and OA163. These findings are in keeping with
previous studies that have identified hypertrophic markers in degenerated IVD tissues. A
study by Sato et al. demonstrated significant increases in Runx2 transcript levels in human
IVDs with moderate degeneration compared to healthy controls176. Rutges et al. also
localized RUNX2, among other hypertrophic markers, to the NP and AF of degenerated
human IVD tissues177. MMP13 is among the most highly expressed MMPs in degenerated
IVD tissues95,96. Consistent with the downregulation in Mmp13 expression we demonstrate
in the Panx3-/- mice, previous studies have suggested a correlation between Panx3 and
MMP13 expression in OA cartilage141. These data may point to a subtle protective role for
the loss of Panx3 in the IVD, where there seems to be a delay in expression of hypertrophic
markers at the onset of degeneration. However, these changes do not appear to be sufficient
to overcome other factors contributing to the multifactorial degenerative process.
Consequently, at 24 month-of-age, we no longer detect differences in gene expression
between WT and Panx3-/- mice.
Given the changes in gene expression of hypertrophic chondrocyte markers, coupled with
the role of Panx3 in promoting hypertrophic differentiation of chondrocytes, we considered
the possibility that Panx3 may be regulating hypertrophic-like changes in the AF. However,
immunohistochemical analysis of COL10, MMP13 and RUNX2 revealed no overt changes
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between WT and Panx3-/- mice. Subtle changes were detected in COL10 localization at 12
and 18 months-of-age, specifically at the AF-CEP interface. This is intriguing given that
this IVD sub-compartment has been previously shown to express mineralization-associated
molecules such as alkaline phosphatases and collagen type X, where collagen fibers from
the AF extend through the CEP to insert into the calcified endplate of the vertebral bone
54

. This bone-AF interface contains a mixed population of chondrocytes and AF cells54,

thus it is tempting to speculate that cells in this region may express high levels of Panx3.
The altered localization of markers of hypertrophy in Panx3-/- mice may suggest a role for
Panx3 related to the integration of bone and IVD tissue; however, further investigations
are required to address this possibility. The subtle changes in protein expression within
IVD sub-compartments associated with loss of Panx3, however, do not appear to impact
the overall progression of age-associated degeneration in the IVD.
The lack of overt phenotype in pannexin knockout mouse models is not uncommon. Work
by Penuela et al. and Bond et al. has highlighted the seemingly normal anatomy and overall
health of several Panx1 knockout mouse models reported in the literature134,174,178–180.
Similarly, initial characterization of the Panx3-/- mouse model used in this study
demonstrated relatively normal long bone development, with no overt differences detected
in growth plate formation or the size of the animals141. Since then, detailed characterization
of the long bones of these mice has revealed subtle differences in parameters such as
muscle attachment sites and lengths of diaphyses181. It should be acknowledged however
that two additional Panx3 null mouse models have been previously reported, both of which
display more prominent abnormalities in skeletal growth182,183. The reason for these
phenotypic discrepancies between published Panx3 null mice remains elusive, but is
suggested to relate to differences in Cre drivers and/or mouse strains184.
Interestingly, studies have reported more robust phenotypes in pannexin knockout mice in
response to exogenous stress. For example, Panx1 knockout mice show no major skin
phenotype; however, after wounding they show significant delays in wound closure and
increasingly fibrotic scar formation compared to WT174. A study by Petric et al. in cardiac
tissues demonstrated an absence of structural and functional abnormalities in Panx1
knockout mice; however, following programmed intracardiac electrical stimulation, these
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mice had a higher incidence of atrial fibrillation185. Additionally, Panx3 deletion prevented
cartilage breakdown and the induction of OA specifically following joint destabilization141.
Results from the current study using an injury-induced model of IVD degeneration support
the notion that additional stressors may be needed to highlight the role of pannexins in the
IVD.
Following needle puncture injury and subsequent NP depressurization, AF tissues in
Panx3-/- mice maintained their structural integrity and lamellar organization compared to
AF tissues of WT mice, which showed disorganized lamellar structures and significant
increases in lamellar width. Measurements of lamellar width captured both the thickness
of individual lamella as well as inter-lamellar spaces, two variables previously shown to
increase with age and IVD degeneration44,186. Additionally, WT mice displayed a
consistent accumulation of large, rounded cells in the AF which were rarely present in
Panx3-/- tissues. These cells were associated with increased pericellular GAG staining and
appeared to contribute to AF lamellar disorganization. The presence of these enlarged AF
cells has been previously association with degenerated IVD tissues; however, the
phenotype of these cells remains poorly understood102,173,187. These data suggest that,
similar to what was observed in OA141, Panx3-/- mice are protected from injury-induced
degeneration in the AF. Of interest however, was the observation that uninjured IVDs
located directly distal to the injured disc in Panx3-/- mice showed accelerated NP
degeneration on the side of injury, changes not detected in WT mice. In humans,
accelerated degeneration of IVDs adjacent to immobilized motion segments following
spinal fusion is commonly reported and suggested to be a consequence of the altered
mechanical stress transferred to the tissue20,188.
In addition to injured WT IVDs, enlarged GAG-associated AF cells were identified in our
model of age-associated IVD degeneration. While detected in both WT and Panx3-/- aging
IVDs, this change in cell morphology appeared more pronounced in WT AF tissues. Given
these findings, it is intriguing to speculate that changes in AF cell morphology associated
with degeneration in Panx3-expressing tissues are a cell adaptive response to alterations in
mechanical loading and contribute to preservation of tissue homeostasis at adjacent IVD
levels. Our analysis of these cells in the context of age-associated IVD degeneration
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revealed that they did not express classical markers of hypertrophic chondrocytes.
Additionally, analysis of injured IVDs revealed that these cells maintain SOX9 expression,
a transcription factor that promotes expression of collagen type II and aggrecan189. While
purely speculative, it seems reasonable that the accumulation of hypertrophic, GAGproducing cells in the AF could be an adaptive response to loss of NP function, a process
which our data suggests may be Panx3-dependent (Fig. 4.1). These cells may act to buffer
mechanical stresses by synthesizing an altered ECM in an attempt to withstand the
additional compressive loads transferred from the depressurized NP. This, in turn, may
help to dampen transmission of aberrant loads to adjacent IVD tissues, and thus providing
protection against degenerative tissue changes. Whether Panx3 is directly involved in
mediating these cellular changes requires future investigation. Nevertheless, these data
seem to support a role for Panx3 in mediating the ability of AF cells to respond to altered
mechanical stress.
Depending on context, Panx3 has been shown to play both physiological and pathological
roles in musculoskeletal tissues. Our analyses demonstrate that Panx3 does not play a
significant role in the progression of age-associated IVD degeneration and that, similar to
other tissues, may be more involved in responding to tissue stress. We show that Panx3 is
highly expressed in the AF where it seems to play a role in mediating responses to altered
mechanical load, which may be involved in preventing the propagation of aberrant loads
across spinal segments. While our work focused on exploring the role of Panx3 in the IVD,
our studies also provide insight on the mechanisms by which WT IVD tissues adapt to
mechanical stress and how these changes relate to the progression of IVD degeneration.
Additionally, this work supports that of others in the field highlighting the interdependent
nature of the distinct disc tissues as well as motion segments across the spine, reinforcing
the need to study the IVD not only as a whole, but also as an integrated part of the vertebral
column.
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Figure 4.1. Schematic illustrating the proposed role of Panx3 in an injury-induced
model of IVD degeneration.
Following NP depressurization, cells of the AF appear to respond to acute changes in
loading environment by secreting a GAG-rich ECM detected in the inter-lamellar matrix
(pink pericellular region), associated with an increase in cell size. While these changes
contribute the widening of inter-lamellar spaces, the altered AF matrix may also contribute
to the buffering of loads being transmitted to adjacent motion segments. These changes
appear to be Panx3-dependent evidenced by the lack of changes to AF cells in Panx3-/mice despite a similar loss of NP tissue integrity. In the absence of the adaptive AF cellular
response to altered mechanical stress in the Panx3-/- mice, aberrant loads from the injured
IVD appear to be more readily transferred to adjacent motion segments, contributing to
degenerative changes in the adjacent IVD. A potential mechanism that may explain these
changes is increased aggrecan expression in Panx3-expressing cells, which may be
mediated by Sox9 activity. Dark shaded NP regions represent degenerative changes.
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4.1. Limitations of Research and Future Directions
It is important to acknowledge certain limitations associated with this work. The first is the
use of a whole-body knockout mouse model. Whole-body loss of Panx3 expression makes
it difficult to conclude if changes observed in our study were a direct result of Panx3
deletion in the AF or if they may be attributed, at least in part, to changes in cells of the
CEP or vertebral bones, tissues that likewise express Panx3. Future investigations using
tissue-specific Cre drivers to delete Panx3 in distinct compartments of the IVD would
provide further insight on the tissue-specific role of Panx3 highlighted in the present work.
Another limitation of our study is the exclusive use of in vivo models. While mouse models
provide a clear advantage in being able to study a protein of interest within its native
environment and the consequences of in situ loss of function, our lack of in vitro work
prevented us from addressing questions of mechanism. Future in vitro studies could be
designed using primary AF cells from WT and Panx3-/- mice to directly investigate if
mechanical loading induces Panx3 activation in the IVD. Additionally, such studies would
permit for the analysis of the cellular function of Panx3 in the IVD, such as its role as a
conduit for ATP and its associated downstream effectors.
Future studies may also look to investigate the progression of IVD degeneration in the
Panx1/Panx3 double knockout mouse model generated by our group (unpublished). While
our data suggests a lack of compensatory Panx1 expression in Panx3-/- mice, we cannot
ignore the possibility of increased endogenous Panx1 activity, particularly at the later time
points where we show elevated Panx1 expression in WT mice. Future investigations using
this double knockout mouse model may help to address the possibility of functional
compensation in our studies of age-associated IVD degeneration, and may bring to light a
potential role for Panx1 in our injury model of IVD degeneration.
Lastly, the ultimate goal of this field of work is to translate our findings to a clinically
relevant application. As such, our findings require validation in human IVD tissues. Given
access to appropriate antibodies or cell-type specific samples, future studies could be
designed to assess Panx3 expression and localization in human IVD tissues, and assess
whether changes in expression are associated with degeneration. Additionally, studies
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using cultured human IVD cells and pannexin inhibitors may help to discern its functional
role in human tissues.
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Supplementary Figure 1. Representative sections of positive and negative controls
used for immunohistochemical analyses.
Negative control sections were run in parallel to those stained with anti-COL10, MMP13,
RUNX2, or SOX9 primary antibody. COL10 and SOX9 staining was run alongside slides
incubated in blocking solution overnight in the absence of primary antibody. IgG isotype
controls were included for MMP13 and RUNX2 immunostaining. No evidence of positive
staining was detected in negative control sections.
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